Page 6 - Brain Dysfunction News Today

Weeks of sedation, months of rehab and perhaps years of lingering symptoms is typical for people who have ended up in an ICU because of COVID.

Long COVID’s laundry list of ills include skepticism and doubt often conveyed in the doctors’ office.

Up to one-third of Covid-19 survivors report experiencing long Covid symptoms afterward. Many of them are being stifled or dismissed.

Coronavirus Disease Weekly News 18April 2021 The news posted last week for the coronavirus 2019-nCoV (aka SARS-CoV-2), which produces COVID-19 disease, has been surveyed and some important articles are summarized here. The articles are more or less organized with general virus news and anecdotes first, then stories from around the US, followed by an increased number of items from other countries around the globe. Economic news related to COVID-19 is found here. Please share this article - Go to...

Search jobs 09-Apr-2021 Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death) - Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in patients treated w...

(0) INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte (INCY) on Thursday said their late-stage study of baricitinib in hospitalized Covid-19 patients did not achieve the main goal. The phase III study dubbed Cov-Barrier of baricitinib plus standard of care (SoC) versus placebo plus SoC did not meet statistical significance on the primary endpoint. The main goal was defined as the difference in the proportion of participants progressing to the first occurrence of non-invasive venti...

Share this article Share this article INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation incl...

Akili Akili, which made history last summer by earning regulatory clearance for the first video-game based therapy, now plans to test if its software can help adults suffering from Covid “brain fog.” Two randomized remote studies, one conducted by Weill Cornell Medicine and New York-Presbyterian Hospital and the other by Vanderbilt University Medical Center, will assess whether AKL-T01, the treatment that Akili commercially markets for ADHD as EndeavorRx, can help improve cognition symptoms...

The human side of healing: How seeing loved ones helps COVID-19 patients COVID-19 restrictions are keeping many patients isolated in the hospital, but a new study is highlighting what doctors, patients and families have seen: being near loved ones can play a role in healing — specifically around a common brain dysfunction that comes with COVID-19. Social Sharing Lancet study on 2,088 patients showed family visitation linked to less delirium, a common risk of COVID-19 Posted: Feb 26, 2021 4:00...

Vanderbilt University Medical Center Wesley Ely, MD, MPH, co-director of the Critical Illness, Brain Dysfunction, and Survivorship Center at VUMC and senior author. Newswise — Delirium, a form of acute brain dysfunction, is widespread in critically ill patients in lower resourced hospitals, and the duration of delirium predicted both mortality and disability at six months after discharge, according to a study published in PLOS ONE.  Working with partners in Zambia, Vanderbilt University Med...